Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 14620507)

  • 1. Starlike vs. classic macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs.
    Jelínková M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
    Pharm Res; 2003 Oct; 20(10):1558-64. PubMed ID: 14620507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
    Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
    Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo effect of HPMA copolymer-bound doxorubicin targeted to transferrin receptor of B-cell lymphoma 38C13.
    Kovár M; Strohalm J; Ulbrich K; Ríhová B
    J Drug Target; 2002 Feb; 10(1):23-30. PubMed ID: 11996083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene.
    Ríhová B; Jelínková M; Strohalm J; St'astný M; Hovorka O; Plocová D; Kovár M; Dráberová L; Ulbrich K
    Bioconjug Chem; 2000; 11(5):664-73. PubMed ID: 10995209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties.
    Etrych T; Jelínková M; Ríhová B; Ulbrich K
    J Control Release; 2001 May; 73(1):89-102. PubMed ID: 11337062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.
    Tomalova B; Sirova M; Rossmann P; Pola R; Strohalm J; Chytil P; Cerny V; Tomala J; Kabesova M; Rihova B; Ulbrich K; Etrych T; Kovar M
    J Control Release; 2016 Feb; 223():1-10. PubMed ID: 26708020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab')(2)-targeted conjugates and combined therapy with immunomodulators.
    Ríhová B; Jelínková M; Strohalm J; Subr V; Plocová D; Hovorka O; Novák M; Plundrová D; Germano Y; Ulbrich K
    J Control Release; 2000 Feb; 64(1-3):241-61. PubMed ID: 10640661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
    Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
    J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.
    Kovár M; Mrkvan T; Strohalm J; Etrych T; Ulbrich K; Stastný M; Ríhová B
    J Control Release; 2003 Oct; 92(3):315-30. PubMed ID: 14568412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
    Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
    J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.
    Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Ríhová B; Ulbrich K
    J Control Release; 2006 Sep; 115(1):26-36. PubMed ID: 16899320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.
    Etrych T; Subr V; Strohalm J; Sírová M; Ríhová B; Ulbrich K
    J Control Release; 2012 Dec; 164(3):346-54. PubMed ID: 22759979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy.
    Etrych T; Kovář L; Strohalm J; Chytil P; Ríhová B; Ulbrich K
    J Control Release; 2011 Sep; 154(3):241-8. PubMed ID: 21699933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.
    Ríhová B; Strohalm J; Hovorka O; Subr V; Etrych T; Chytil P; Pola R; Plocová D; Boucek J; Ulbrich K
    J Control Release; 2008 Apr; 127(2):110-20. PubMed ID: 18325618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting.
    Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Boucek J; Ríhová B; Ulbrich K
    J Control Release; 2008 Apr; 127(2):121-30. PubMed ID: 18304673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.
    Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T
    Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
    Etrych T; Mrkvan T; Ríhová B; Ulbrich K
    J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparison of in vivo properties of water-soluble HPMA-based polymer conjugates with doxorubicin prepared by controlled RAFT or free radical polymerization.
    Chytil P; Šírová M; Koziolová E; Ulbrich K; Říhová B; Etrych T
    Physiol Res; 2015; 64(Suppl 1):S41-9. PubMed ID: 26447594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates.
    He S; Zhou Z; Li L; Yang Q; Yang Y; Guan S; Zhang J; Zhu X; Jin Y; Huang Y
    Drug Deliv; 2016; 23(1):285-96. PubMed ID: 24865288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of systemic antitumour resistance with targeted polymers.
    Rihova B; Strohalm J; Kovar M; Mrkvan T; Subr V; Hovorka O; Sirova M; Rozprimova L; Kubackova K; Ulbrich K
    Scand J Immunol; 2005 Jul; 62 Suppl 1():100-5. PubMed ID: 15953192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.